A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes

Inclusion Criteria:

- adult patients, 18-75 years of age;

- type 2 diabetes mellitus;

- treated with stable sulfonylurea monotherapy or metformin + sulfonylurea for >=12
weeks prior to screening;

- HbA1c >=7.0% and <=10% at screening;

- stable weight +/-5% for >=12 weeks prior to screening.

Exclusion Criteria:

- type 1 diabetes, diabetes resulting from pancreatic injury, or secondary forms of
diabetes;

- clinically significant diabetic complications;

- clinically symptomatic gastrointestinal disease;

- >3 episodes of severe hypoglycemia within 6 months before screening.